These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 797502)

  • 21. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.
    Kurth MC
    Drugs Aging; 1997 May; 10(5):332-40. PubMed ID: 9143854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pathomechanism of dyskinesia associated with treatment of Parkinson disease with levodopa].
    Friedman A
    Neurol Neurochir Pol; 1981; 15(4):407-9. PubMed ID: 6173792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic optimisation in the treatment of Parkinson's disease.
    Contin M; Riva R; Albani F; Baruzzi A
    Clin Pharmacokinet; 1996 Jun; 30(6):463-81. PubMed ID: 8792058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
    Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract]   [Full Text] [Related]  

  • 26. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of chronic levodopa treatment on pyridoxine metabolism.
    Mars H
    Neurology; 1975 Mar; 25(3):263-6. PubMed ID: 1167634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease.
    Wenning GK; O'Connell MT; Patsalos PN; Quinn NP
    Mov Disord; 1995 Sep; 10(5):664-7. PubMed ID: 8552121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
    Harder S; Baas H; Rietbrock S
    Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When should levodopa therapy be initiated in patients with Parkinson's disease?
    Halkias IA; Haq I; Huang Z; Fernandez HH
    Drugs Aging; 2007; 24(4):261-73. PubMed ID: 17432922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
    Rinne UK; Marttila R
    Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outpatient treatment of Parkinson's disease.
    Wermuth L
    Eur Neurol; 1988; 28(3):152-5. PubMed ID: 3383913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 36. [L-dopa induced dyskinesia in Parkinson's disease].
    Bastide MF; Bézard E
    Bull Acad Natl Med; 2015; 199(2-3):201-12. PubMed ID: 27476302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Interaction of L-DOPA and pyridoxine (a review of the literature)].
    Uspenskiĭ AE
    Farmakol Toksikol; 1977; 40(6):722-33. PubMed ID: 340258
    [No Abstract]   [Full Text] [Related]  

  • 38. Intermittent levodopa therapy in parkinsonism.
    Koller WC
    Adv Neurol; 1983; 37():45-50. PubMed ID: 6407286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG
    Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.